The inflammatory responses in Alzheimer's disease (AD) and prion-related encephalopathies (PRE) are dominated by microglia activation. Several studies have reported that the amyloid-beta (Ab) peptides, which are associated with AD, and the pathogenic isoform of prion protein (PrP Sc ) have a crucial role in neuronal death and gliosis that occur in both of these disorders. In this study, we investigate whether Ab and PrP Sc cause microglia activation per se and whether these amyloidogenic peptides differentially affect these immunoeffector cells. In addition, we also determined whether substances released by Ab-and PrPactivated microglia induce neuronal death. Cultures of rat brain microglia cells were treated with the synthetic peptides Ab 1-40 , Ab 1-42 and PrP 106-126 for different time periods. The lipopolysaccharide was used as a positive control of microglia activation. Our results show that Ab 1-40 and PrP 106-126 caused similar morphological changes in microglia and increased the production of nitric oxide and hydroperoxides. An increase on inducible nitric oxide synthase expression was also observed in microglia treated with Ab 1-40 or PrP 106 . However, these peptides affected in a different manner the secretion of interleukin-1b (IL-1b) and interleukin-6 (IL-6) secretion. In cocultures of microglia-neurons, it was observed that microglia treated with Ab 1-40 or PrP 106-126 induced a comparable extent of neuronal death. The neutralizing antibody for IL-6 significantly reduced the neuronal death induced by Ab-or PrP-activated microglia. Taken together, the data indicate that Ab and PrP peptides caused microglia activation and differentially affected cytokine secretion. The IL-6 released by reactive microglia caused neuronal injury. V V C 2006 Wiley-Liss, Inc.
Microglia are the immunocompetent cells of the CNS, playing an important role in brain homeostasis maintenance. These cells are very sensitive to changes in the surrounding environment and readily become activated in response to infection or injury (Streit, 2002; Liu and Hong, 2003) . Microglia activation is a gradual process, involving cell proliferation and migration to the site of injury, as well as morphological and functional changes. Activated microglia have an amoeboid morphology, up-regulate several surface receptors, and secrete a large variety of soluble factors, such as cytokines, chemokines, proteases, reactive oxygen species (ROS), and nitric oxide (NO; Lee et al., 2002; Davalos et al., 2005) . Although some of these factors promote neuronal and glial survival, most are neurotoxic and proinflammatory (Liu and Hong, 2003; van Rossum and Hanisch, 2004) . Thus, it is widely accepted that microglia activation provides an initial protective role, whereas a persistent activation of these cells and the consequent sustained secretion of inflammatory factors contribute to neuronal death that occurs in neurodegenerative diseases.
Prion-related encephalopathies (PRE) and Alzheimer's disease (AD) are neurodegenerative disorders characterized neuropathologically by the presence of extracellular amyloid deposits, extensive neuronal loss, and gliosis. In AD, the amyloid deposits are composed of amyloid-beta (Ab) peptides (40-42 amino acids), which result from the abnormal proteolytic cleavage of amyloid precursor protein, whereas, in PRE, the amyloid deposits are constituted mainly of the scrapie isoform of prion protein (PrP Sc ), a conformational variant of the cellular prion protein (PrP C ). The amyloid deposits are generally colocalized with reactive microglia, inflammatory factors, and dystrophic neurites (Nelson et al., 2002; Liu and Hong, 2003) . Increasing evidence suggests that microglia activation is concomitant with Ab and PrP Sc deposition and precedes neuronal death (Marella and Chabry, 2004; Veerhuis et al., 2005) . Indeed, microglia are considered to be involved in neuroinflammation and, consequently, in the progression of AD and PRE Veerhuis et al., 2005) . In the present study, we analyzed whether Ab and PrP differentially activate microglia cells and whether microglia treated with these peptides trigger neuronal death. The synthetic peptides Ab 1-40 , Ab , and PrP , which are widely used to mimic the effect of Ab and PrP Sc , were utilized to stimulate cultured rat brain microglia cells. Morphological changes and molecular responses induced by these peptides in microglia cells were determined and compared with microglial reactions to lipopolysaccharide (LPS), a well-known inductor of inflammation. Cocultures of microglia/neurons were used to investigate whether the substances released by Ab-and PrP-activated microglia cause neurodegeneration.
MATERIALS AND METHODS

Materials
Neurobasal medium and B-27 supplement were purchased from Gibco (Paisley, United Kingdom). Synthetic peptides of Ab and PrP were from Bachem (Bubendorf, Switzerland). The rat anti-ED1 (clone ED1), rabbit anti-inducible nitric oxide synthase (iNOS; clone pAb), and rat anti-interleukin-6 (IL-6) antibodies were obtained from Serotec (Oxford, United Kingdom), BD Biosciences (Erembodegem, Belgium), and R&D Systems (Minneapolis, MN), respectively. Alexa Fluor IgG conjugated secondary antibodies, 2 0 ,7 0 -dichlorofluorescin diacetate, Amplex red hydrogen peroxide/peroxidase assay kit (A-22188), and Hoechst 33342 were acquired from Molecular Probes (Leiden, The Netherlands). The fluorescent mounting medium was from DakoCytomation (Glostrup, Denmark). ELISA kits for rat interleukins were obtained from R&D Systems (Abingdon, United Kingdom). Millicell culture plate inserts were from Millipore (Bedford, MA). Reagents and apparatus used in immunoblotting assays were obtained from Bio-Rad (Hercules, CA), whereas PVDF membranes, alkaline phosphatase-linked antimouse secondary antibody, and the enhanced chemifluorescence (ECF) reagent were from Amersham Biosciences (Buckinghamshire, United Kingdom). Percoll solution was also purchased from Amersham Biosciences. All other reagents, including LPS (Escherichia coli O26:B6), were from Sigma Chemical Co. (St. Louis, MO).
Microglia Cell Cultures
Primary microglial cell cultures were obtained from neonatal Wistar rats 5-7 days old, according to the method described by Kingham and colleagues (1999) , with some modifications. In brief, after cervical dislocation and decapitation of rats, the brains were removed and placed in ice-cold phosphate buffer solution [PBS (in mM) 140 NaCl, 4 KCl, 8.5 KH 2 PO 4 , 7.4, Na 2 HPO 4 , pH 7.4]. After removal of the cerebellum, they were cut into small pieces and homogenized. The brain homogenate was then centrifuged at 500g for 10 min at 48C. The pellet was resuspended in a 70% Percoll solution. The 70% Percoll-cell mixture was then overlaid with 35% Percoll and finally with PBS. The Percoll gradient formed was centrifuged at 1,300g for 45 min at 208C, and the microglia cells were collected at the 35%/70% interface. Then, the cells were mechanically dissociated, through a 5-ml glass pipette, and washed in PBS (five times the cell volume collected) at 500g for 10 min at 208C. Dissociated microglia cells were ressuspended in astrocytes conditioned medium (ACM) and counted in a hemocitometer. The ACM was obtained from rat brain astrocytes cultured in DMEM medium supplemented with 10% fetal calf serum and penicillin (100 U/ml) and streptomycin (100 lg/ml; Sastradipura et al., 1998) . The microglia cells were cultured in filtered ACM (pH 7.4) at 378C in an atmosphere containing 95% air and 5% CO 2 . The cells were plated in plastic plates or in cell culture inserts (membrane pore size 0.4 lm) at a density of 0.2 3 10 6 cells/ cm 2 or in glass coverslips at 0.1 3 10 6 cells/cm 2 . Twenty-four hours after plating, the medium was changed and the cells were treated with the peptides or LPS for different periods of time. The morphological analysis and immunoreactivity toward microglial marker complement receptor type 3 using anti-CD11b monoclonal antibody (1:50; Serotec) and antiglial fibrillary acid protein (GFAP) polyclonal antibody (1:200; DakoCytomation) had shown that these cultures are constituted of >95% microglia (data not shown).
Neuron-Microglia Cocultures
Primary cultures of cortical cells were prepared from 15-16-day embryos of Wistar rats according to the method described by Agostinho and Oliveira (2003) . Cortical cells were cultured in Neurobasal medium with 2 mM L-glutamine, 2% B27 supplement, penicillin (100 U/ml), and streptomycin (100 lg/ml). The neurons were plated on poly-L-lysine (0.1 mg/ml)-coated coverslips at a density of 0.6 3 10 6 cells/cm 2 and maintained at 378C in a humidified atmosphere of 5% CO 2 /95% air. Microglia cells cultured in inserts, for 1 day, were placed into the wells containing the neurons, with 5 days in culture. These cocultures were maintained in ACM medium, and the treatment with the peptides or with LPS started 16 hr afterward. The distance between the microglia (inserts) and neurons (coverslips) was approximately 1 mm.
Treatment With Peptides
Cultured microglia cells were treated with Ab 1-40 or Ab 40-1 (5 lM), Ab 1-42 (0.5 lM), PrP 106-126 (25 lM), and scrambled PrP (25 lM) for different periods ranging from 3 to 24 hr, as indicated in the figure legends. The peptides were added into culture medium at the second culturing day. The peptides were reconstituted according to the manufacturer's instructions, and Ab 1-40 or Ab 40-1 peptides were aged in PBS buffer, in a stock concentration of 231 lM, for 7 days at 378C to obtain fibrillar Ab. LPS (0.1 lg/ml) was added to cultured microglia as indicated for peptides. Cells not treated (control) or treated with 2.1% PBS (vehicle control) were used as controls.
Immunocytochemistry
Microglia cells cultured in glass coverslips were treated with peptides or LPS. Then, the cells were washed with PBS and fixed with a 4% paraformaldehyde solution (pH 7.4) for 30 min at room temperature (RT). The cells were permeabilized with PBS-0.2% Triton X-100 for 2 min at RT, and blocked with 0.1% bovine serum albumin (BSA) in PBS before incubation with a primary antibody for 1 hr at RT. The anti-ED1 (1:500) and anti-iNOS (1:500) monoclonal antibodies was used to recognize an antigen predominant in activated microglia and iNOS, respectively. After being washed in PBS to remove the unbound antibody, they were incubated with labelled anti-mouse Alexa Fluor 594 (for anti-ED1) or anti-rabbit Alexa Fluor 488 (for anti-iNOS) IgG antibodies (1:500) for 1 hr at RT. Finally, the cells were mounted with the DakoCytomation fluorescent medium and visualized via fluorescence microscopy. Figures 1 and 4 show representative images of each experimental condition obtained in three or four independent experiments.
Western Blotting
Treated microglia cells were lysed with ice-cold isolation buffer [250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 (pH 7.4), 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor cocktail]. The lysates were rapidly frozen/defrosted three times and cleared by centrifugation (20,200g for 10 min). The supernatant was collected and assayed for protein content with the Bio-Rad reagent. The proteins were separated by electrophoresis on 10% SDS-PAGE and transferred electrophoretically to a PVDF membrane (Agostinho and Oliveira, 2003) . To facilitate the identification of proteins, a prestained precision protein standard (Bio-Rad) was used. iNOS was detected by immunodetection using a rabbit anti-iNOS monoclonal antibody (1:500) and an alkaline phosphate-conjugated secondary antibody (1:20,000). All experiments were repeated in at least three independent cell preparations. Bands of immunoreactive protein were visualized, after membrane incubation with ECF reagent for 5 min, on a Versadoc image system. Densities of blot bands were calculated in the Quantity One program (Bio-Rad). 
Nitrite Assay
NO production was determined by the nitrite(NO 2 -) assay with the Griess reagent (0.1% N-[1-naphtyl]ethylenediamine dihydrochloride, 1% sulphanilamide and 2% phosphoric acid). This colorimetric method is based on the measurement of NO 2 -, a stable endproduct of the reaction between NO and molecular oxygen. After microglial cell incubation with peptides or LPS, culture supernatants and cell lysates (50 ll) were mixed with an equal volume of Griess reagent for 15 min in the dark at RT, according to the method described by Huygen (1970) . Absorbance was measured at 550 nm with a microplate reader. The nitrite concentration was determined from a sodium nitrite standard curve ranging from 0 to 100 lM. All experiments were performed in duplicate, in four to six independent cell preparations. The total nitrite concentration produced by microglia cells was calculated by adding the nitrites in cellular supernatant and in cell lysates.
Analysis of Reactive Oxygen Species Production
After microglia treatment with the peptides or LPS, the ROS production was evaluated through the Amplex red assay and by using a fluorescent method.
Amplex red assay. The intracellular levels of hydroperoxides, mainly H 2 O 2 , were measured by using the Amplex red hydrogen peroxide/peroxidase assay kit. Samples from cell lysates of microglia treated with peptides or LPS, as well as standard curve samples, were incubated with a reaction mixture that contains Amplex red reagent (10-acetyl-3,7-dihydroxyphenoxazine) and horseradish peroxidase, according to the manufacturer's instructions. All experiments were performed in duplicate, in three to six independent cell preparations. Absorbance was read at 570 nm in a microplate reader.
Fluorimetric DCF method. The levels of intracellular peroxides were detected with a nonfluorescent compound, 2 0 ,7 0 -dichlorofluorescin diacetate (DCFH 2 -DA), which permeates the cells and is desterified by esterases to acid 2 0 ,7 0 -dichlorofluorescin. This ionized acid is trapped in the cells and can be oxidized to fluorescent 2 0 ,7 0 -dichlorofluorescein (DCF) by hydroperoxides (Cathcart et al., 1983) . Microglia cells cultured in glass coverslips, after being treated with peptides or not, were incubated with 5 lM DCFH 2 -DA, as described previously by Agostinho and Oliveira (2003) . The different experimental conditions were repeated in three to six independent cell preparations. DCF fluorescence was measured at 502 nm excitation and 550 nm emission and expressed as arbitrary units.
Cytokine Release Assessment
The levels of interleukin-1b (IL-1b) and IL-6 were determined in culture supernatants of microglia cells (0.2 3 10 6 cells/cm 2 ) treated with the peptides or LPS by using enzyme-linked immunosorbent assay (ELISA) kits specific for rat IL-1b and IL-6. The samples of culture supernatants, controls, and standards were pipetted into microplates of these ELISA kits, according to the manufacturer's instructions (R&D Systems). The experiments were performed in duplicate, in four to six independent cell preparations. The absorbance of formed products was measured at 450 nm, with the correction wavelength at 540 nm, in a microplate reader. The sample values were read off the standard curve and expressed as picograms per milliliter of cell supernatant.
Neuronal Viability Evaluation
Neuronal death was assessed by fluorescence microscopy with the fluorescent DNA stain Hoechst 33342. Dead cells (mainly apoptotic) have fragmented or irregularly stained chromatin, whereas viable cells display homogeneous staining. Neurons plated in glass coverslips were incubated for 5 min with 300 ll of Hoechst 33342 (10 lg/ml) in the dark. After being washed with PBS, the cells were observed in a fluorescence microscope. Those cells showing irregular and relatively high blue fluorescence (dead cells) were identified from an average of 300 cells per treatment and cell batch. Each individual experiment, made in duplicate, was repeated in four different cell preparations. The cells were examined by blinded counting. Four pictures from different fields (selected randomly) were taken from each individual experiment, in which all the cells (6 300) were counted. Data are expressed as the percentage of dead cells among the total cells counted.
Statistical Analysis
Results are expressed as means 6 SEM of the number of experiments indicated in the figure legends. Statistical significance was determined by using an analysis of variance (ANOVA), followed by Dunnett's posttests, or by using the two-tailed Student's t-test (as indicated in Fig. 7 ).
RESULTS
To characterize the activation of microglia induced by Ab and PrP, the synthetic peptides Ab 1-40 , Ab 1-42 (the major components of amyloid plaques in AD), and PrP 106-126 (a peptide fragment that mimics PrP Sc toxicity and forms fibrils in vitro; Combs et al., 1999) were used to stimulate cultured rat microglia cells. The scrambled PrP (PrP scram ) and the reverted peptide Ab 40-1 were used in some experiments as negative controls. In addition, the bacterial endotoxin LPS, a classic inductor of glial activation in vitro, was used as a positive control. Studies performed by our group have shown that Ab 1-40 and Ab 1-42 were added to cultures in a fibrillar form, which was maintained during the time periods in culture (Resende et al., personal communication) . We have also observed that PrP 106-126 forms fibrils, but its neurotoxic effects are independent of aggregation state (Melo et al., unpublished data). Taking into account preliminary assays in which the effect of different concentrations (0.5-5 lM) of each peptide on microglia morphology and NO production was tested, we used 5 lM Ab 1-40 , 0.5 lM Ab 1-42 , or 25 lM PrP 106-126 . These concentrations induced significant microglia activation (data not shown).
Morphological Alterations of Microglia
The morphological changes of microglia induced by Ab and PrP peptides were visualized through phasecontrast microscopy and by assessing the immunoreactiv-ity to anti-ED-1 antibody, which binds to ED-1 receptor (also designated CD68) of activated microglia with high affinity . As can be observed in Figure 1 , the synthetic peptides Ab 1-40 and PrP 106-126 induced changes in shape and size of microglia cells, compared with untreated cells (control). LPS also caused alterations in microglial morphology. Microglial cells treated with Ab 1-40 (5 lM), PrP 106-126 (25 lM), or LPS (0.1 lg/ml) for 3 hr have a rounded, ameboid morphology, have phase-bright cell soma, and exhibit small and thick branches. A similar pattern of morphologic alterations was observed in microglia treated with 0.5 lM Ab 1-42 (data not shown). Control cells have an elongated shape and ramified cell bodies. Moreover, it was observed that microglia treated with peptides crowd together and form clusters, whereas control cells were dispersed. An intense immunoreactivity against ED-1 (red fluorescence) was also observed in microglia treated with peptides or LPS, compared with control cells (Fig. 1) , indicating that morphological alterations induced by Ab and PrP peptides are a sign of microglia activation. These morphologic and immunophenotypic alterations became evident upon 3 hr of treatment with peptides and LPS and were maintained for at least 24 hr (data not shown). The effect of PBS (2.1%) was also tested on microglia morphology. PBStreated cells (vehicle control) exhibit a ramified morphology and low ED-1 immunoreactivity, similar to untreated cells (data not shown).
Microglia Molecular Responses
Since microglial activation also involves functional alterations, we further investigated whether Ab and PrP peptides affect the production and/or release of some inflammatory and neurotoxic factors.
Reactive nitrogen and oxygen species production. Figure 2 shows the levels of NO produced by cultured microglia cells treated with Ab and PrP peptides for different incubation times. The levels of NO in microglia treated with Ab 1-40 (1.28 6 0.10 lM/lg protein), Ab 1-42 (1.12 6 0.08 lM/lg protein), and PrP (1.65 6 0.20 lM/lg protein) for 3 hr were higher than, but not significantly different (P > 0.05) from, those observed in control cells (1.05 6 0.26 lM/lg protein). However, at 6 hr of incubation, these peptides caused a The concentration of nitrite, a stable NO product, was determined by the Griess assay. Values represent the total concentration of nitrite, determined in cell lysates and culture supernatants, expressed as lM/ lg protein. Data are means 6 SEM of four to six independent experiments. *P < 0.05, ***P < 0.001, significantly different from control cells under the same experimental conditions. significant (P < 0.05) increase of about 50% in the levels of NO produced compared with untreated cells (control) or PBS-treated cells (vehicle control). For longer periods of incubation, 12 hr and 24 hr, no significant differences were observed between NO produced by Ab-or PrPtreated cells and by controls (untreated and PBS treated). At 6 hr of incubation with Ab 1-40 and PrP 106-126 , we was observed a significant increase in the amount of NO produced by microglia, so we analyzed whether the reverse sequence of Ab, Ab 40-1 , and the scrambled PrP 106-126 peptide (PrP scram ) affected NO production. In the presence of these peptides, which are not neurotoxic (Agostinho and Oliveira, 2003) , the levels of NO produced were similar to the level determined in control cells, suggesting that microglia molecular responses triggered by Ab 1-40 and PrP 106-126 were specific for these amino acid sequences. The effect of Ab 1-42 (0.5 lM) in NO production was similar to that obtained with Ab 1-40 (5 lM), at all incubation times studied (Fig. 2) ; therefore, in the following experiments, we used the smallest peptide. The effect of LPS (0.1 lg/ml) on NO production by microglia was also evaluated and, as expected, it was observed that this toxin significantly (P < 0.001) increased NO levels (Fig. 2) .
To determine whether the increase in NO production caused by Ab and PrP peptides was correlated with alterations in iNOS expression, we determined the levels of this protein in control cells and in cells treated with Ab 1-40 (5 lM) or PrP 106-126 (25 lM). We analyzed the levels of iNOS at 6 hr of incubation, because an increase in NO production at this incubation time was observed. The results obtained via immunoblotting showed that iNOS levels in microglia treated with Ab 1-40 (1.46 6 0.03 a.u.) or PrP 106-126 (1.58 6 0.05 a.u.) were significantly (P < 0.05) higher than those determined in control cells (1.04 6 0.02 a.u). LPS (0.1 lg/ml) also augmented (P < 0.01) iNOS levels (Fig. 3) . To provide additional evidence that Ab and PrP peptides affect the expression of iNOS, immunocytochemistry studies were performed to visualize the iNOS expression in cells treated with those peptides. As can be seen in Figure 4 , the anti-iNOS fluorescence labelling (green) was more intense in cells treated with Ab 1-40 , PrP 106-126 , or LPS than in control cells. The images of differential interference contrast (DIC) are also displayed (Fig. 4) to show that, under control conditions, the number of cells labelled with the anti-iNOS antibody was lower than that in cells treated with the peptides or LPS. These data support those obtained from immunoblotting (Fig. 3) , showing that Ab and PrP peptides augmented iNOS expression. This increase in iNOS expression can explain the rise in NO production observed in microglia treated with these amyloidogenic peptides (Fig. 2) .
Microglial activation may involve the production of ROS that can react with NO forming others reactive nitrogen species (Andersen, 2004) . To examine whether Ab 1-40 and PrP 106-126 peptides trigger ROS production in microglia cells, we determined the intracellular hydroperoxides levels. By using the Amplex red assay, we measured the hydroperoxides levels in cell lysates of microglia treated with the peptides or LPS (Fig. 5A) . The levels of ROS in microglia treated with Ab 1-40 (16.4 6 1.4 lM/lg protein) and PrP 106-126 (16.6 6 3.0 lM/lg protein), for 3 hr, was higher than that determined in untreated cells (11.2 6 0.8 lM/lg protein). PBS (2.1%) was without effect on ROS production (data not shown). This significant increase in ROS levels (about 46%) was similar to that determined in microglia treated with Ab 1-40 or PrP 106-126 for 6 hr (50% 6 2%) and 12 hr (48% 6 2%) compared with control cells (data not shown). A significant (P < 0.01) enhancement in ROS levels was also observed in cells treated with LPS (Fig. 5A) . A 3-hr incubation with Ab 1-40 and PrP 106-126 significantly enhanced ROS, so we monitored the ROS production in living microglia cells treated with peptides for this period. As can be seen in Figure 5B , the ROS levels produced by microglia cells treated with Ab 1-40 or PrP 106-126 were significantly (P < 0.01) higher than those formed in the absence of peptides. These data are in agreement with those obtained from the Amplex red assay and suggest , and LPS (0.1 lg/ml) for 6 hr. Cell lysates were examined by immunoblotting with an anti-iNOS (130 kDa) monoclonal antibody, as described in Materials and Methods. The blot was stripped and reprobed with antiactin antibody (clone C4; Chemicon) to estimate the total amount of protein loaded in gel. Immunoreactive bands were visualized by scanning on a Versadoc Image system, and the levels of proteins were quantified in the Quantity One program. Bars represent the relative levels of iNOS, compared with actin, and were expressed as arbitrary units. Data are the means 6 SEM of three independent experiments. Representative blots of iNOS and actin are shown. *P < 0.05, **P < 0.01, significantly different from control cells. that Ab and PrP peptides triggered ROS production in microglia.
Cytokine secretion. In Alzheimer's and prion diseases cytokines are thought to promote Ab and PrP neurotoxicity (Hanisch, 2002; Hoozemans et al., 2002; Nelson et al., 2002) . Therefore, we analyzed whether Ab 1-40 and PrP 106-126 peptides affect the secretion of interleukin-1b (IL-1b) and interleukin 6 (IL-6) by microglia cells. The levels of these cytokines were measured in culture supernatants of microglia treated with the peptides for 3, 6, 12, and 24 hr (Fig. 6) . Ab 1-40 increased IL-6 secretion significantly (P < 0.01) after 12 hr of incubation, whereas PrP 106-126 raised the secretion of this cytokine at an early phase. Indeed, as can be seen in Figure 6A , cells treated with PrP 106-126 for 3-6 hr secreted significantly (P < 0.05) more IL-6 than under control conditions or even after Ab 1-40 treatment. However, at 12 hr of incubation either Ab 1-40 or PrP 106-126 increased the IL-6 secretion by about 170% or 90% (above control values), respectively. These data suggest that Ab 1-40 is more efficient in inducing IL-6 secretion than PrP . The levels of IL-6 secreted by microglia treated with Ab 1-40 or PrP 106-126 for 12 hr were not significantly different from those determined at 24 hr of incubation, indicating that IL-6 secretion reached a plateau upon 12 hr of incubation with the peptides. The effect of Ab 1-42 (0.5 lM) on IL-6 secretion was also evaluated for 3, 6, 12, and 24 hr. Similarly to what was observed with Ab 1-40 , Ab 1-42 caused a significant increase in IL-6 secretion only after 12 hr of incubation, the amounts of cytokine released at 12 hr and 24 hr being 380.5 6 12.7 pg/ml and 367.2 6 30.0 pg/ml, respectively. LPS significantly increased IL-6 secretion for all incubation times studied (Fig. 6A) . Figure 6B shows that IL-1b secretion was not significantly affected by Ab 1-40 , whereas PrP 106-126 caused a significant (P < 0.05) increase in the release of IL-1b at 6 hr of incubation. This enhancement in IL-1b secretion was maintained for longer incubation periods (12-24 hr). The levels of IL-1b secreted by microglia treated with Ab 1-40 for 48 hr were also determined, but no significant augmentation was observed (data not shown), suggesting that this peptide was not able to trigger IL-1b secretion. Likewise, Ab 1-42 (0.5 lM), tested for 3-24 hr, did not significantly (P > 0.05) affect IL-1b release compared with control cells (data not shown). Similarly to what was observed for NO and ROS production, PBS (2.1%, vehicle control) did not affect IL-1b or IL-6 secretion (data not shown). Taken together, these results indicate that Ab 1-40 and PrP 106-126 affected microglial cytokines secretion in a distinct manner. The ROS levels, measured by the Amplex red (A), were expressed as lM/lg protein and by arbitrary units of DCF fluorescence (B). Data are means 6 SEM of three to six independent experiments. *P < 0.05, **P < 0.01, significantly different from control cells under the same experimental conditions.
Neurodegeneration Caused by Microglia Activated by Ab and PrP Peptides
To evaluate whether the substances released by Abor PrP-activated microglia cause neuronal death, we used cocultures of microglia-neurons (Mic-Neu). Ab 1-40 (5 lM), PrP 106-126 (25 lM), or LPS (0.1 lg/ml) was added to culture plate inserts containing microglia cells. In these cocultures, the substances released by microglia can reach neurons by diffusing through the membrane porous (0.4 lm) of inserts. Figure 7 shows that, in cocultures treated with Ab 1-40 , PrP 106-126 , or LPS, the percentage of dead neurons was significantly (P < 0.01) higher than in untreated cocultures (control). These data suggest that the substances released by Ab-, PrP-, or LPSactivated microglia triggered neuronal death. Because we observed that microglial secretion of IL-6, but not of IL1b, was significantly augmented by Ab and PrP treatments, the effect of a neutralizing antibody for IL-6 was evaluated in cocultures. With the presence of the antibody (50 ng/ml), we observed a significant (P < 0.05) reduction (about 40%) of neuronal death after microglia treatment with Ab or PrP. The anti-IL-6 antibody also significantly (P < 0.05) prevented the neuronal death induced by LPS-treated microglia (Fig. 7 , Mic-Neu þ anti-IL-6). Similar effects were observed with 100 ng/ml anti-IL-6 antibody (data not shown). Because in these cocultures systems the peptides can diffuse through porous membrane, we determined whether Ab 1-40 , PrP 106-126 , and LPS added to inserts without microglia affect neuronal viability (Fig. 7, Neu) . When the inserts without microglia cells were used, the Ab 1-40 and PrP 106-126 , but not LPS, caused significant (P < 0.05) neuronal injury. Although neuronal death in cocultures (Mic-Neu) could be partially due to a direct effect of the peptides on neu- Fig. 7 . Neuronal death induced by Ab-and PrP-activated microglia in the presence or absence of a neutralizing antibody for IL-6. Ab 1-40 (5 lM), PrP 106-126 (25 lM), or LPS (0.1 lg/ml) was added into inserts containing microglia cells that were cocultured with cortical neurons (Mic-Neu), for 24 hr. When the effect of anti-IL-6 antibody was tested in these cocultures system (Mic-Neu þ anti-IL-6), 50 ng/ml of antibody was added to neuronal cultures just prior the treatment of microglia (in inserts) with the peptides or LPS. A similar system using inserts without cells, which were placed in wells containing the cultured neurons (Neu), was also used to determine the direct effect of peptides on neuronal viability (see Results). After incubation with the peptides or LPS in the presence or absence of anti-IL-6, inserts were removed, and the neuronal cells were labelled with Hoechst 33342. The number of dead and viable cells was determined, analyzing the nuclear morphology. Data are expressed as a percentage of dead cells relative to the total number of cells counted (6300 cells per treatment and cell batch) and are means 6 SEM of four independent experiments. *P < 0.05, **P < 0.01, significantly different from control cells under the same experimental conditions (Mic-Neu, Mic-Neu þ anti-IL-6, or Neu); þ P < 0.05 compared with cells treated with the same peptide or LPS in the presence of anti-IL-6 antibody (two-tailed Student's t-test). (25 lM), or LPS (0.1 lg/ml) for 3, 6, 12, and 24 hr. The levels of interleukin-6 (A) and interleukin-1b (B), in control cells and in cells treated with the peptides or LPS, were determined in culture supernatants by ELISA, as described in Materials and Methods. The amount of cytokines released is expressed as pg/ml cell supernatant. Data are means 6 SEM of four to six independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from control cells under the same experimental conditions. rons, the data suggest that IL-6 released by microglia treated with Ab 1-40 , PrP 106-126 , or LPS triggered neurodegeneration.
DISCUSSION
Several studies have reported that Ab and PrP synthetic peptides induce microglia activation in biological models containing neurons and/or astrocytes. In these cell systems, the activation of microglia is influenced not only by the peptides but also via substances released by injured cells Eskes et al., 2003) . In this study, we used pure cultures of rat brain microglia cells to investigate whether Ab and PrP synthetic peptides, per se, differentially activate these immunoeffector cells. The microglia culture system used, despite being maintained in astrocyte-conditioned media, did not include reactive astrocytes or the multitude of other cytokines and factors released by them that certainly contribute to trigger neurodegeneration (von Bernhardi and Eugenín, 2004; Schultz et al., 2004) . Moreover, the effect of substances released by Ab-and PrP-activated microglia cells in neuronal viability was also evaluated by using cocultures, where neurons can be separated before cell death analysis. Therefore, this defined cell system can be useful in identifying initial and specific targets that might contribute to the development of therapeutic strategies to treat AD and PRE.
Microglia activation involves multiple pathways that result in morphological alterations, proliferation, changes in phagocytic competence, and production of bioactive molecules, which can modulate a large spectrum of functional activities (Streit et al., 1999) . In this study, we observed that cultured rat brain microglia cells exposed to Ab 1-40 or PrP 106-126 underwent considerable changes in morphology and ED-1 immunoreactivity in a time-dependent manner, with the alterations starting to be evident after 3 hr treatment. The morphological and immunophenotypical alterations of microglia induced by these peptides were similar to those observed in cells treated with LPS, a strong inductor of glial activation in vitro (Fig. 1) . These data suggest that Ab and PrP synthetic peptides induced changes in microglia morphology that are correlated with the activation process.
The substances released by activated microglia have been pointed out as essential elements in the onset and progression of neurodegenerative diseases, such as AD and PRE (Streit, 2002; Nelson et al., 2002; Liu and Hong, 2003) . NO can be an important signalling molecule; however, when it reacts with superoxide, it can form peroxynitrite that might act as a neurotoxic factor (Fabrizi et al., 2001; Xie et al., 2002; Liu and Hong, 2003) . Our results show that Ab 1-40 , Ab 1-42 , and PrP 106-126 caused a significant peak in microglial NO production, at 6 hr incubation, whereas LPS induced a huge increase in NO levels that was maintained for all incubation periods tested. Under our experimental conditions, the increases in NO production induced by Ab and PrP peptides were accompanied by an increase in ROS levels, mainly hydroperoxides. Indeed, by using two different assays (DCF and Amplex red), a significant increase was observed in microglial ROS production, at a relatively early phase of peptide exposure (3-6 hr). Xie and colleagues (2002) reported that peroxynitrite is the major mediator of the neurotoxicity induced by Aband LPS-activated microglia cells. The brains of AD patients exhibit high levels of nitrotyrosine, which result from the reaction of peroxynitrite with tyrosine residues of proteins (Smith et al., 1997) , suggesting a participation of NO and ROS in this disorder. Moreover, ROS can promote the aggregation of amyloid fragments and consequently the formation of amyloid deposits (Van Everbroeck et al., 2004) . Therefore, the early release of NO and ROS may be an essential factor in AD and PRE progression.
It is known that stressful conditions can trigger the expression of iNOS, which can generate NO from Larginine (Vallance and Leiper, 2002) . We observed that Ab 1-40 and PrP 106-126 , after 6 hr incubation, significantly increased the iNOS levels of microglia. Accordingly, other studies have reported that Ab and PrP synthetic peptides induce iNOS expression, by measuring the levels of mRNA and/or of protein (Fabrizi et al., 2001; von Bernhardi and Eugenín, 2004) , and it was also stated that iNOS expression is increased in the brains of PrP Scinfected animals (Ju et al., 1998; Williams et al., 1997) and of AD patients (Luth et al., 2002) . A great variability in the incubation time with peptides needed to induce changes in iNOS expression and NO production has been reported in different studies. These discrepancies probably are due to experimental conditions used, such as the presence of astrocytes or neurons, source (human, rat, mouse) of microglia cells, culture age and density, as well as culture media composition. Indeed, a recent study stated that Ab peptides induce higher increases in iNOS levels and NO production in pure microglia cultures than in mixed glial cell cultures (von Bernhardi and Eugenín, 2004) .
Cytokines are signalling proteins that are thought to participate in several events in CNS, such as immunoregulation, intercellular communication, and neurodevelopment. IL-1b and IL-6 are important effector cytokines, acting as immunostimulatory and proinflammatory factors (Hanisch, 2002) . Both these cytokines have been identified in amyloid plaques, near activated microglia, and it is widely suggested that they play an important role in neurodegeneration (Hanisch, 2002; Hoozemans et al., 2002; Nelson et al., 2002) . Our data show that PrP 106-126 , but not Ab 1-40 , augmented the IL-1b secretion by microglia. Moreover, it was observed that IL-6 secretion was induced only by PrP 106-126 at an early phase (3-6 hr), but Ab 1-40 was more efficient than PrP 106-126 for longer incubation periods, inducing a higher production of this cytokine. In accordance with our results, it was shown that PrP 106-126 induces IL-6 and IL-1b release in cultured mouse microglia (Peyrin et al., 1999; Veerhuis et al., 2002) , and fibrillar Ab is unable to induce IL-1 (b and a) release (Li et al., 2004) .
On the contrary, it was reported that Ab 25-35 peptide (without fibrillogenic capacity) treatment for 24 hr induces the release of IL-1b but not of IL-6 (Lee et al., 2002) . Recent studies have reported that the activation of human microglia and the consequent release of cytokines induced by Ab and PrP are increased by complement factors C1q and serum amyloid P, which are usually associated with amyloid deposits in AD and PRE (Veerhuis et al., 2003 (Veerhuis et al., , 2005 . Our data suggest that microglia cells react differentially to Ab and PrP peptides in IL-1b and IL-6 secretion. The differences between Ab-and PrP-evoked IL-1b and IL-6 release and the LPS-evoked release are remarkable, probably because peptides induce subtoxic responses, whereas the endotoxin caused an unusual and toxic response. In a paper by Combs and colleagues (1999) , comparing microglia responses to Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and PrP 106-126 , it was reported that both peptides activate identical tyrosine kinase-dependent inflammatory signal transduction cascades that lead to production of neurotoxic substances. These signal pathways are also activated by classical immune stimulus of inflammation, and their primary downstream targets are transcription factors that positively modulate the expression of proinflammatory factors (Combs et al., 1999 (Combs et al., , 2000 . Our data reinforce these findings, in that we observed that microglia cells were similarly affected by Ab and PrP peptides as concerns ROS and NO production as well as levels of iNOS expression.
Activated microglia secrete a wide range of substances, including, in addition to those already mentioned, various neurotoxic factors that could represent the outcome of a coordinated program of intracellular signalling events mediating proinflammatory and neurotoxic responses (Fabrizi et al., 2001; Hanisch, 2002) . By uing cocultures of microglia-neurons, we have observed that substances released by microglia treated with Ab 1-40 and PrP , as well as with LPS, caused neuronal injury. The blockade of IL-6 physiological effects, by using a neutralizing anti-IL-6 antibody, significantly prevented the neurodegeneration caused by Ab-, PrP-, and LPS-activated microglia. In accordance with these results, several groups have reported that IL-6 exposure compromises neuronal viability (Qiu et al., 1998; Nelson et al., 2004) . On the other hand, it was also stated that this cytokine can be neuroprotective and neurotrophic in several pathological conditions (Carlson et al., 1999; Hanisch, 2002; Peng et al., 2005) . Indeed, the tendency of IL-6 for a proinflammatory or an antiinflammatory effect is probably determined by its concentration and the simultaneous presence of other factors, such as cytokines. We can speculate that IL-1b was not involved in the neurotoxicity triggered by activated microglia because IL-1b secretion increased only after PrP or LPS treatments and not in Ab-activated microglia, although the extent of neuronal death was similar in cocultures treated with Ab, PrP, or LPS. Although the data suggest that IL-6 released by microglia treated with Ab 1-40 , PrP 106-126 , or LPS triggered neurodegeneration, the neuronal death in cocultures could be due partially to peptide diffusion through the porous membrane of inserts, resulting in a direct effect on neurons (see results obtained when peptides and LPS were added to the insert without microglia; Fig. 7 , Neu). In accordance, previous reports from our group and others show that Ab and PrP peptides are neurotoxic (Combs et al., 1999; Agostinho and Oliveira, 2003) .
In conclusion, our data show that Ab and PrP peptides, per se, induced microglia activation and increased the production of ROS and NO as well as of iNOS expression. However, these peptides seemed to have a different time lag in inducing IL-6 release and dissimilar effects on IL-1b secretion, indicating that Ab and PrP differentially affect cytokines secretion by microglia. The IL-6 released by activated microglia contributes to neurodegeneration. Thus, pharmacological interventions targeting prevention of IL-6 secretion and/or its cellular effects can be useful in treating AD and PRE.
